All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2023-12-06T10:49:32.000Z

Patient case discussion on treating with CELMoDs

Dec 6, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in relapsed/refractory MM.

Bookmark this article

During the Multiple Myeloma Hub Steering Committee Meeting in November 2023, key opinion leaders met to discuss patient cases on treatment with Cereblon E3 ligase modulator (CELMoDs). This recorded discussion was chaired by Paul Richardson and featured Sagar Lonial, María-Victoria Mateos, Heinz Ludwig, Hermann Einsele, Morie Gertz, Elena Zamagni, and Meral Beksac.

Patient case discussion on treating with CELMoDs

This session opened with a presentation from Paul Richardson in which they shared the mechanism of action, latest clinical data, and applications for CELMoDs in multiple myeloma. Richardson highlighted iberdomide and mezigdomide as novel agents and discussed the latest data from trials on their use both as monotherapies and in combination.

The panel discussed differences between the two agents, the incorporation of these drugs into the myeloma treatment landscape, and optimal combination treatments. The experts concluded by discussing the incidence of secondary malignancies associated with these agents and the applications of CELMoDs in extramedullary multiple myeloma.

Downloadable presentation

To download this resource, click below.

Download here

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox